What is eliglustat tartrate used for?
Eliglustat tartrate (Cerdelga) is used to treat adults with Gaucher disease type 1, a genetic condition where a fatty substance (glucosylceramide) builds up because of deficient activity of the enzyme glucocerebrosidase. Eliglustat helps reduce that buildup by slowing the production of the material that accumulates.
Who is it prescribed for in Gaucher disease type 1?
In practice, eliglustat is prescribed for adults with Gaucher disease type 1 who meet medication-use requirements based on how their body breaks down the drug (metabolism), which can affect safety and dosing. [1]
How does eliglustat work (and how is that different from enzyme replacement)?
Eliglustat is an oral therapy that acts by inhibiting the pathways that lead to glucosylceramide synthesis. That’s different from enzyme replacement therapies, which supply the missing enzyme directly.
What patients ask about most: can it be used with other Gaucher treatments?
Whether eliglustat can be combined with other Gaucher disease treatments depends on the patient’s situation and the prescriber’s plan. The key practical issue is drug–drug interactions and the suitability of the patient’s metabolic profile for eliglustat dosing. [1]
Where does the evidence come from?
Eliglustat is approved as a treatment option for Gaucher disease type 1 based on clinical studies showing it can reduce the disease-causing substrate and improve clinical measures compared with baseline, with eligibility depending on patient factors such as metabolism. [1]
Sources
[1] https://www.drugpatentwatch.com/